Skip to main content
. 2023 Jun 8;10:1166024. doi: 10.3389/fmed.2023.1166024

Table 2.

Comparison of blood pressure, cardiovascular parameters between the two groups of PD patients at baseline and after 24 months of follow-up.

Roxadustat (n = 60) rHuEPO (n = 60)
Baseline variable After 24  months of follow-up Change from baseline Baseline After 24  months of follow-up Change from baseline
Systolic blood pressure (mmHg) 131.3 ± 15.9 130.0 ± 12.5 −1.28 ± 13.4 131.1 ± 15.9 138.1 ± 14.0*# 7.02 ± 15.1#
Diastolic blood pressure (mmHg) 85.0 ± 10.2 83.1 ± 7.7 −1.93 ± 9.0 83.8 ± 10.1 89.8 ± 9.4*# 5.35 ± 10.8#
Nocturnal hypertension, n (%) 8 (13.3) 5 (8.3) −3 (−5) 7 (11.7) 18 (30)*# 11 (18.3)#
Urine volume (mL) 1,100 (112–1457.5) 1,075 (157.5, 1437.5) −50 (−100, 0) 1,100 (725–1337.5) 800 (450, 1087.5)*# −200 (−487, −50)#
Weight (kg) 59.4 ± 9.9 57.8 ± 10.4 −0.4 ± 4.4 60.2 ± 10.8 59.7 ± 11.9 −0.0 ± 6.8
NT-proBNP (pmol/L) 170.2 (56.5, 475.8) 114.3 (34.4, 300.5) −5.4 (−167.2, 158.5) 119.1 (60.1, 456.3) 424.4 (155.5, 1350.5)*# 95.3 (−17.2, 494.0)#
TnT (ng/mL) 0.019 (0.014, 0.034) 0.027 (0.021, 0.064) 0.007 (−0.004, 0.019) 0.021 (0.0125, 0.036) 0.066 (0.047, 0.0995)*# 0.048 (0.029, 0.072)#
TnI (ng/mL) 0.03 (0.02, 0.03) 0.0275 (0.015, 0.03) 0.005 (0,0.015) 0.035 (0.025, 0.04) 0.05 (0.0395, 0.06)*# 0.02 (0.01, 0.04)#
IVS (mm) 9.94 ± 1.52 10.03 ± 1.75 −0.09 ± 1.74 10.26 ± 1.92 10.52 ± 1.53 0.28 ± 1.82
LVPW (mm) 9.94 ± 1.23 10.06 ± 1.85 −0.38 ± 1.40 9.78 ± 1.43 10.1 ± 1.42 0.26 ± 1.94
LVEF (%) 62.8 ± 4.5 63.2 ± 4.8 0.9 ± 6.7 63.8 ± 6.1 60.9 ± 4.7*# −3.3 ± 7.1#
Cardiothoracic ratio 0.48 ± 0.06 0.49 ± 0.04 −0.02 ± 0.05 0.48 ± 0.05 0.51 ± 0.07* 0.04 ± 0.06#

NT-proBNP, N-terminal pro-brain natriuretic peptide; TnT, troponin T; TnI, troponin I; IVS, interventricular septal; LVPW, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction.

Compared with baseline, *p<0.05; Compared with roxadustat group, #p<0.05.